GrayBug Vision IPO

9/24/2020

IPO

$90,000,000

Management says it will use the net proceeds from the IPO as follows:approximately $17.0 million to fund the development of GB-102, including $6.1 million for the completion of our ongoing Phase 2b clinical trial in wet AMD, $1.8 million for the initiation of our Phase 2b clinical trial in DME, $8.5 million for the initiation of our Phase 3 clinical trials in wet AMD, subject to the success of the Phase 2b trial, and $0.6 million for the initiation of our GB-401 Phase 1 clinical trial in glaucoma;approximately $20.8 million to fund Chemistry, Manufacturing and Controls, or CMC, capital expenditures;approximately $8.4 million to fund arrangements with contract manufacturing organizations to manufacture clinical material for our wet AMD and glaucoma clinical trials; andany remaining amounts for working capital and general corporate purposes.

Publicly-held

Medical Devices & Instruments

275 Shoreline Dr. 450
Redwood City, CA 94065
USA

Graybug Vision (Nasdaq: GRAY) is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies.